ANALYSIS OF THE L’OREAL GROUP’S MARKETING STRATE
World Journal of Information and Knowledge Management · 2023
DOI: 10.61784/wjikm231112 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Information and Knowledge Management, 2023. Verfasst von Hongyan Li und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In China's FMCG market, the highly competitive cosmetics industry is one of the hottest areas. As a leading enterprise in the cosmetics industry, L'Oreal Group has a number of well-known brands involved in skincare, hairdressing, perfumery and other fields, such as HR, Kérastase, Giorgio Armani, etc. L'Oreal Group has been in China for more than 20 years, and it has encountered many challenges, but there are also many marketing success stories. In this paper, the macro environment is analyzed by the PEST model. Through the analysis and research of the classic 4P theoretical framework of marketing, it can be found that L'Oreal Group's marketing strategy in the Chinese market is mainly manifested in terms of products, prices, channels and promotions, and puts forward optimization suggestions for L'Oreal's marketing strategy in China: improve e-commerce channels, strengthen the publicity of its local brands, and focus on the showroom phenomenon.
Zitieren
APA
Li, H., Xu, S., Lou, C., Shen, L., & Zhu, M. (2023). ANALYSIS OF THE L’OREAL GROUP’S MARKETING STRATE. World Journal of Information and Knowledge Management. https://doi.org/10.61784/wjikm231112
Vancouver
Li H, Xu S, Lou C, Shen L, Zhu M. ANALYSIS OF THE L’OREAL GROUP’S MARKETING STRATE. World Journal of Information and Knowledge Management. 2023. doi:10.61784/wjikm231112
BibTeX
@article{Li2023,
author = {Li, Hongyan and Xu, Siyi and Lou, Chenxin and Shen, Li and Zhu, Mengli},
title = {ANALYSIS OF THE L’OREAL GROUP’S MARKETING STRATE},
journal = {World Journal of Information and Knowledge Management},
year = {2023},
doi = {10.61784/wjikm231112}
}
EUVIMED